Your browser doesn't support javascript.
loading
Biomarkers of NRF2 signalling: Current status and future challenges.
Morgenstern, Christina; Lastres-Becker, Isabel; Demirdögen, Birsen Can; Costa, Vera Marisa; Daiber, Andreas; Foresti, Roberta; Motterlini, Roberto; Kalyoncu, Sibel; Arioz, Burak I; Genc, Sermin; Jakubowska, Monika; Trougakos, Ioannis P; Piechota-Polanczyk, Aleksandra; Mickael, Michel; Santos, Marlene; Kensler, Thomas W; Cuadrado, Antonio; Copple, Ian M.
Afiliação
  • Morgenstern C; Department of Otorhinolaryngology, Medical University of Vienna, General Hospital of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria; Institute of Molecular Biosciences, University of Graz, Humboldtstraße 50, A-8010, Graz, Austria.
  • Lastres-Becker I; Department of Biochemistry, School of Medicine, Universidad Autónoma de Madrid (UAM), Spain; Instituto de Investigación Sanitaria La Paz (IdiPaz), Instituto de Investigaciones Biomédicas "Sols-Morreale" UAM-CSIC, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerati
  • Demirdögen BC; Department of Biomedical Engineering, TOBB University of Economics and Technology, Ankara, Turkey.
  • Costa VM; Associate Laboratory i4HB - Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Porto, Portugal; UCIBIO - Applied Molecular Biosciences Unit, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal.
  • Daiber A; Department of Cardiology 1, University Medical Center of the Johannes Gutenberg University, Mainz, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany.
  • Foresti R; University Paris-Est Créteil, INSERM, IMRB, F-94010, Créteil, France.
  • Motterlini R; University Paris-Est Créteil, INSERM, IMRB, F-94010, Créteil, France.
  • Kalyoncu S; Izmir Biomedicine and Genome Center, Izmir, Turkey.
  • Arioz BI; Izmir Biomedicine and Genome Center, Izmir, Turkey; Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir, Turkey.
  • Genc S; Izmir Biomedicine and Genome Center, Izmir, Turkey; Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir, Turkey; Department of Neuroscience, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.
  • Jakubowska M; Malopolska Centre of Biotechnology, Jagiellonian University, ul. Gronostajowa 7a, 30-387, Krakow, Poland.
  • Trougakos IP; Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Athens, 15784, Greece.
  • Piechota-Polanczyk A; Department of Cell Cultures and Genomic Analysis, Medical University of Lodz, 90-752, Lódz, Poland.
  • Mickael M; Department of Experimental Genomics, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, Postepu 36A, 05-552, Garbatka, Poland.
  • Santos M; REQUIMTE/LAQV, Escola Superior de Saúde, Instituto Politécnico do Porto, Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.
  • Kensler TW; Translational Research Program, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA.
  • Cuadrado A; Department of Biochemistry, School of Medicine, Universidad Autónoma de Madrid (UAM), Spain; Instituto de Investigación Sanitaria La Paz (IdiPaz), Instituto de Investigaciones Biomédicas "Sols-Morreale" UAM-CSIC, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerati
  • Copple IM; Department of Pharmacology & Therapeutics, Institute of Systems, Molecular & Integrative Biology, University of Liverpool, Liverpool, L69 3GE, UK. Electronic address: ian.copple@liverpool.ac.uk.
Redox Biol ; 72: 103134, 2024 06.
Article em En | MEDLINE | ID: mdl-38643749
ABSTRACT
The cytoprotective transcription factor NRF2 regulates the expression of several hundred genes in mammalian cells and is a promising therapeutic target in a number of diseases associated with oxidative stress and inflammation. Hence, an ability to monitor basal and inducible NRF2 signalling is vital for mechanistic understanding in translational studies. Due to some caveats related to the direct measurement of NRF2 levels, the modulation of NRF2 activity is typically determined by measuring changes in the expression of one or more of its target genes and/or the associated protein products. However, there is a lack of consensus regarding the most relevant set of these genes/proteins that best represents NRF2 activity across cell types and species. We present the findings of a comprehensive literature search that according to stringent criteria identifies GCLC, GCLM, HMOX1, NQO1, SRXN1 and TXNRD1 as a robust panel of markers that are directly regulated by NRF2 in multiple cell and tissue types. We assess the relevance of these markers in clinically accessible biofluids and highlight future challenges in the development and use of NRF2 biomarkers in humans.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores / Transdução de Sinais / Estresse Oxidativo / Fator 2 Relacionado a NF-E2 Limite: Animals / Humans Idioma: En Revista: Redox Biol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Áustria

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores / Transdução de Sinais / Estresse Oxidativo / Fator 2 Relacionado a NF-E2 Limite: Animals / Humans Idioma: En Revista: Redox Biol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Áustria